‹ ›
MYP_022129
← PREVIOUS NEXT → BACK
Basic Information
SPMI-HIF1-1
Anticancer
Standard
18 amino acids
C94H133N19O28
Standard
Sequence
TSFSEYWSLLSALAAYAP
Physicochemical Analysis
1977.17 Da
4.05
-1.60
-1.80
-0.0889
0.49
0.33
0.38
38.24
87.22
0.2222
8480.00
8480.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
743.93
-5.56
27.0
27.0
56.0
141.0
6.0
17.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0160505 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
MDM2/MDMX-binding peptide
32630
Structure & Mods
hydrocarbon-stapled side-chain cyclic peptide [Cyclic]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
Stapled: Ⓧ(4) and Ⓧ (8) are cross-linked by hydrocarbon stapling
Bio-Activity Profile
Anticancer
HCT116 p53+/+
57.7 μM
IC50
PaperChen S, Li X, Li Y, Yuan X, Geng C, Gao S, Li J, Ma B, Wang Z, Lu W, Hu HG. Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression. Theranostics. 2022 Sep 11;12(15):6665-6684. PMID36185610 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/36185610/
RECORD: Rec_0188868 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
MDM2/MDMX-binding peptide
32630
Structure & Mods
hydrocarbon-stapled side-chain cyclic peptide [Cyclic]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
Stapled: Ⓧ(4) and Ⓧ (8) are cross-linked by hydrocarbon stapling
Bio-Activity Profile
Anticancer
HCT116 p53+/+
82.1 μM
IC50
PaperChen S, Li X, Li Y, Yuan X, Geng C, Gao S, Li J, Ma B, Wang Z, Lu W, Hu HG. Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression. Theranostics. 2022 Sep 11;12(15):6665-6685. PMID36185610 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/36185610/
RECORD: Rec_0259203 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
MDM2/MDMX-binding peptide
32630
Structure & Mods
hydrocarbon-stapled side-chain cyclic peptide [Cyclic]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
Stapled: Ⓧ(4) and Ⓧ (8) are cross-linked by hydrocarbon stapling
Bio-Activity Profile
Anticancer
HCT116 p53+/+
85.1 μM
IC50
PaperChen S, Li X, Li Y, Yuan X, Geng C, Gao S, Li J, Ma B, Wang Z, Lu W, Hu HG. Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression. Theranostics. 2022 Sep 11;12(15):6665-6685. PMID36185610 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/36185610/
RECORD: Rec_0318935 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
MDM2/MDMX-binding peptide
32630
Structure & Mods
hydrocarbon-stapled side-chain cyclic peptide [Cyclic]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
Stapled: Ⓧ(4) and Ⓧ (8) are cross-linked by hydrocarbon stapling
Bio-Activity Profile
Anticancer
HCT116 p53-/-
>100 μM
IC50
PaperChen S, Li X, Li Y, Yuan X, Geng C, Gao S, Li J, Ma B, Wang Z, Lu W, Hu HG. Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression. Theranostics. 2022 Sep 11;12(15):6665-6684. PMID36185610 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/36185610/